

February 1, 2022

Paul Edick
Chairman and Chief Executive Officer
Xeris Biopharma Holdings, Inc.
180 N. LaSalle Street, Suite 1600
Chicago, Illinois 60601

Holdings, Inc.

Statement on Form S-3
2022

Re: Xeris Biopharma

Registration

Filed January 28,

File No. 333-262403

Dear Mr. Edick:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Michael

Davis at 202-551-4385 with any questions.

Sincerely,

Division of Corporation Finance

Office of Life Sciences

Joseph C. Theis, Jr.,

cc:
Esq.